The Form 4 filing, a report of an insider's stock trades, was filed on November 10, 2026. The sales took place four days earlier, on November 6, 2026. Venkat Achanta is listed as an executive vice president at TransUnion (TRU).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-06 |
| Date of Latest Transaction | 2026-11-06 |
| Buy/Sell | sell |
| Transaction Count | 2 |
| Shares Transacted | 29,291 |
| Price | $80.74 |
| Total Transaction Value | $2,364,927.83 |
| Insider | |
| Ticker Symbol | TRU |
| Company | TransUnion |
| Insider Name | Achanta Venkat |
| Insider Title | EVP, Chief Tech, Data & Analy |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 167,621 |
| Position Size Change | 14.88% |
| Filing | |
| Filing Date | 2026-11-10 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were two sales of TransUnion stock, reported under transaction code S, which identifies a sale. They covered 29,291 shares in total.
What was the average price of the transaction?
The average sale price was $80.74 per share across both transactions. Separate prices for each sale are not included in the available transaction details.
How did this transaction affect the insider's holdings?
Venkat Achanta sold 29,291 shares and reported 167,621 shares owned afterward. The sales accounted for 14.88% of his reported shares owned before the sales. The remaining balance shows that he still held shares after these trades.
What's the total transaction value?
The two sales totaled $2,364,927.83 when rounded to cents. The more precise reported value was $2,364,927.831. That total covers both transactions together.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement for these sales. Footnote text was not available, so further terms or circumstances remain unknown. These details do not establish whether the sales were planned in advance or explain why they were made.
For research purposes only; not investment advice.